ClinicalMetric tracks all active clinical trials for graves disease sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.
Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.
Frequently Asked Questions — graves disease Clinical Trials
How many clinical trials are currently recruiting for graves disease?
ClinicalMetric currently tracks 6 actively recruiting clinical trials for graves disease, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 6. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for graves disease?
graves disease research spans Phase 1 (1 trial), Phase 2 (3 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a graves disease clinical trial?
Eligibility criteria for graves disease trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Top Sponsors
argenx 1 trial
Biogen 1 trial
Elazıg Fethi Sekin Sehir Hastanesi 1 trial
Immunovant Sciences GmbH 1 trial
Yarrow Bioscience, Inc. 1 trial
Recruiting Clinical Trials
NCT07596849 Phase 3
Recruiting
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.
Location
Belgium, Bulgaria, C...
NCT07722546 Phase 2
Recruiting
A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old
Location
United States, Puert...
NCT07480720
Recruiting
Systemic Inflammation, Thyroid Autoimmunity and Neuroretinal Changes in Graves Disease
Location
Turkey (Türkiye)
Sponsor
Elazıg Fethi Sekin Sehir Hasta...
View Trial → NCT07018323 Phase 2
Recruiting
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
Location
United States, Austr...
Sponsor
Immunovant Sciences GmbH
View Trial → NCT07682896 Phase 2
Recruiting
Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease
Location
United States, Austr...
Sponsor
Yarrow Bioscience, Inc.
View Trial → NCT07333677 EARLY_Phase 1
Recruiting
In Vivo CAR-T for Refractory Graves' Disease
Sponsor
Shanghai Zhongshan Hospital
View Trial → ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional.
Full Disclaimer ·
Last Reviewed: November 2026 ·
Data Methodology